Israel - Hebräisch - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israel - Hebräisch - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israel - Hebräisch - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israel - Hebräisch - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

Israel - Hebräisch - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - Hebräisch - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - Hebräisch - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - תמיסה לשאיפה - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

Israel - Hebräisch - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

Israel - Hebräisch - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

Israel - Hebräisch - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.